NCT02134249

Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Benha University · Academic / Other
• Sex: Female
• Age: 23 Years – 48 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the effect of oral Diosmin to oral Cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in high-risk women underwent intracytoplasmic sperm injection (ICSI).

Detailed description

Two hundred women at risk of ovarian hyperstimulation syndrome during ICSI cycles will be randomly scheduled into two equal groups. In group A, (Diosmin group), 2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for 2 weeks ; while in group B (Cabergoline group), 1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for eight days.

Conditions

• Infertility

Interventions

Type	Name	Description
DRUG	Diosmin	2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for14 days
DRUG	Cabergoline	1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days

Timeline

• Start date: 2014-04-01
• Primary completion: 2015-09-01
• Completion: 2015-10-01
• First posted: 2014-05-09
• Last updated: 2016-02-02

Locations

2 sites across 1 country: Egypt